What Happened?
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall Street's expectations. Also, the result revealed minimal bottom-line improvement, as the business remained unprofitable. Further weighing on results, the company posted negative free cash flow for the quarter. On the other hand, guidance was more encouraging as full-year sales and EBITDA outlook were both ahead of consensus estimates. Overall, this was a challenging quarter.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy NeoGenomics? Access our full analysis report here, it’s free.
What The Market Is Telling Us
NeoGenomics’s shares are very volatile and have had 22 moves greater than 5% over the last year. But moves this big are rare even for NeoGenomics and indicate this news significantly impacted the market’s perception of the business.
NeoGenomics is down 31.9% since the beginning of the year, and at $11.23 per share, it is trading 39.7% below its 52-week high of $18.61 from January 2025. Investors who bought $1,000 worth of NeoGenomics’s shares 5 years ago would now be looking at an investment worth $329.47.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.